![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 07, 2024 12:33:42 AM
Stomach pain
30 January 2024
Posted in Cancer Research, News | Tagged Cancer treatment, Chemotherapy, Napo Pharmaceuticals, Oncology, Preclinical investigations, Puma Biotechnology
A study in dogs has shown that crofelemer can provide symptomatic relief of diarrhoea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) neratinib (Nerlynx).
Puma Biotechnology’s Nerlynx is a pan HER TKI indicated for the extended adjuvant treatment of adult patients with early stage and metastatic HER2 positive breast cancer.
The study was conducted by Jaguar company Napo Pharmaceuticals in collaboration with Puma Biotechnology.
Cancer therapy-related diarrhoea (CTD) has the potential to cause dehydration, infections and non-adherence to treatment, and is a growing unmet medical need in cancer patients.
“We are very pleased with the results of this prophylactic study, which was undertaken to ‘model’ the human situation with neratinib,” said Lisa Conte, Jaguar’s President and CEO. “Crofelemer, our novel, oral, plant-based, non-opioid antidiarrhoeal prescription medication, is also the subject of OnTarget, Jaguar’s pivotal Phase III clinical trial for the follow-on indication of the preventative treatment of CTD, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB).”
Dr Michael Guy, Jaguar’s Vice President of Preclinical and Nonclinical Studies, added: “The study demonstrated that crofelemer caused an approximate 30% reduction in the incidence and severity of diarrhoea associated with daily oral administration of neratinib, which was statistically significant.”
In a pilot Phase II study in humans, seven patients underwent treatment with crofelemer and loperamide, five of whom were able to control diarrhoea with crofelemer alone.
“Though this study involved a small number of patients, the results show activity of crofelemer for the management of neratinib-induced diarrhea, which warrants further investigation of crofelemer for treatment of cancer therapy-related diarrhea (CTD),” said study investigator Hope Rugo, Professor of Medicine and Winterhof Family Professor of Breast Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 04:19:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/31/2024 10:30:50 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/28/2024 10:03:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 10:20:41 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/23/2024 10:05:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:04:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:03:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:02:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:01:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/21/2024 01:02:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:41:41 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 09:07:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:33 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 12:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:30:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:13:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:25:44 PM
- FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS • PR Newswire (Canada) • 11/15/2023 02:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:03:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 09:03:29 PM
- FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU • PR Newswire (Canada) • 09/21/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:55:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:50:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM